A multi-centre, single arm, Phase 3 study to assess the safety and reactogenicity of biological Es Vi-capsular polysaccharide-CRM197 conjugate typhoid vaccine in ≥6 months old infants to ≤45 years old adults.

A multi-centre, single arm, Phase 3 study to assess the safety and reactogenicity of biological Es Vi-capsular polysaccharide-CRM197 conjugate typhoid vaccine in ≥6 months old infants to ≤45 years old adults.

Background: Typhoid fever is a serious bacterial infection caused by Salmonella Typhi, with a significant burden in low- and middle-income countries, particularly in Sub-Saharan Africa and South/Southeast Asia. To mitigate its spread, the World Health Organization (WHO) advocates for typhoid vaccina...

Full description

Saved in:
Bibliographic Details
Main Authors: Subhash Thuluva, Ramesh V. Matur, Subbareddy Gunneri, Vijay Yerroju, Rammohan Reddy Mogulla, Chirag Dhar, Raju Esanakarra, Savita Verma, Manish Narang, Madhukar Pandey
Format: Article
Language:English
Published: Elsevier 2025-08-01
Series:Vaccine: X
Subjects:
Typhoid
Typhoid conjugate vaccine (TCV)
Salmonella Typhi
Immunization
Online Access:http://www.sciencedirect.com/science/article/pii/S2590136225000634
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2590136225000634

Similar Items